NEW YORK (GenomeWeb) – Vermillion said today that it has received a CE mark for its Overa ovarian cancer test, a second-generation version of its OVA1 test.

The company is now cleared to market Overa in the EU, and is "actively identifying global partnerships" to sell the test, Vermillion President and CEO Valerie Palmieri said in a statement.

Like OVA1, Overa is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.